Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Kreijne JE, de Veer RC, de Boer NK, Dijkstra G, West R, Moorsel SAW, de Jong DJ, van der Woude CJ, de Vries AC; of the Dutch Initiative on Crohn, Colitis (ICC). Kreijne JE, et al. Among authors: van der woude cj. Aliment Pharmacol Ther. 2019 Aug;50(4):407-415. doi: 10.1111/apt.15402. Aliment Pharmacol Ther. 2019. PMID: 31359480
Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study.
West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, Kuipers EJ. West RL, et al. Among authors: van der woude cj, van tilburg aj. Aliment Pharmacol Ther. 2004 Dec;20(11-12):1329-36. doi: 10.1111/j.1365-2036.2004.02247.x. Aliment Pharmacol Ther. 2004. PMID: 15606395 Free article. Clinical Trial.
Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial).
Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AW, Crolla RM, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AM, Davids PH, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieverse RJ, van der Zaag ES, Houben MH, Vecht J, Pierik RE, van Ditzhuijsen TJ, Prins HA, Marsman WA, Stockmann HB, Brink MA, Consten EC, van der Werf SD, Marinelli AW, Jansen JM, Gerhards MF, Bolwerk CJ, Stassen LP, Spanier BW, Bilgen EJ, van Berkel AM, Cense HA, van Heukelem HA, van de Laar A, Slot WB, Eijsbouts QA, van Ooteghem NA, van Wagensveld B, van den Brande JM, van Geloven AA, Bruin KF, Maring JK, Oldenburg B, van Hillegersberg R, de Jong DJ, Bleichrodt R, van der Peet DL, Dekkers PE, Goei TH, Stokkers PC. Eshuis EJ, et al. Among authors: van milligen de wit aw, van berkel am, van hillegersberg r, van heukelem ha, van der peet dl, van ditzhuijsen tj, van der woude cj, van der werf sd, van wagensveld b, van bodegraven aa, van der zaag es, van den brande jm, van geloven aa, van de laar a, van ooteghem na. BMC Surg. 2008 Aug 22;8:15. doi: 10.1186/1471-2482-8-15. BMC Surg. 2008. PMID: 18721465 Free PMC article. Clinical Trial.
Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk.
Festen EA, Stokkers PC, van Diemen CC, van Bodegraven AA, Boezen HM, Crusius BJ, Hommes DW, van der Woude CJ, Balschun T, Verspaget HW, Schreiber S, de Jong DJ, Franke A, Dijkstra G, Wijmenga C, Weersma RK. Festen EA, et al. Among authors: van der woude cj, van bodegraven aa, van diemen cc. Am J Gastroenterol. 2010 Feb;105(2):395-402. doi: 10.1038/ajg.2009.576. Epub 2009 Oct 27. Am J Gastroenterol. 2010. PMID: 19861958
Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.
van Schaik FD, ten Kate FJ, Offerhaus GJ, Schipper ME, Vleggaar FP, van der Woude CJ, Stokkers PC, de Jong DJ, Hommes DW, van Bodegraven AA, Siersema PD, Oldenburg B; Dutch Initiative on Crohn and Colitis. van Schaik FD, et al. Among authors: van der woude cj, van bodegraven aa. Inflamm Bowel Dis. 2011 May;17(5):1108-16. doi: 10.1002/ibd.21467. Epub 2010 Sep 7. Inflamm Bowel Dis. 2011. PMID: 20824815
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
van der Woude CJ, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, D'Haens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW; Initiative on Crohn's and Colitis, The Netherlands. van der Woude CJ, et al. Among authors: van bodegraven aa, van assche g. Inflamm Bowel Dis. 2010 Oct;16(10):1708-16. doi: 10.1002/ibd.21252. Inflamm Bowel Dis. 2010. PMID: 20848453 Clinical Trial.
278 results